Philadelphia's Mayor Killed Needle Funding. The Syringes Being Collected Just Cratered Too.
A program that once moved 10 million syringes a year is down to 1.7 million — and the used ones not coming back in are the real public-health cost.
A city can defund the clean needles and still call itself pro-harm-reduction, as long as it keeps paying for the ambulance. That’s the arithmetic Philadelphia is running right now. Mayor Cherelle Parker has been explicit about it: “While I’m the mayor, I will fight tooth and nail to ensure that not one city dollar is invested in the distribution of clean needles,” she’s said, even while acknowledging syringe exchange is “an important part of the harm-reduction strategy.” Nearly $1 million came out of Prevention Point’s budget for exactly that reason. The program now runs on zero public dollars.
The numbers show what losing that money actually does. Prevention Point distributed and collected 8.8 million syringes in 2022, 8 million in 2023 with over 95% collection. In the 2025-2026 fiscal year: 1.7 million distributed and collected — an 80% collapse from three years ago. Every one of those missing syringes is a needle someone in Philadelphia is now more likely to share, reuse, or find in a park.
We watched this exact trade-off get made once before with catastrophic results. In 2015, Scott County, Indiana saw roughly 200 HIV infections tear through a rural community, traced to needle sharing, while then-Governor Mike Pence — who called himself “opposed to needle exchange as anti-drug policy” — held off on authorizing one until the outbreak was already a national story. Public health researchers still cite Scott County as the textbook case for what “we’ll fund everything except the needles” actually costs, measured in infections a sterile syringe would have prevented.
Prevention Point didn’t shut down — its other services grew even as the syringes shrank. Onsite medical visits are up 128%. Long-acting buprenorphine injections have doubled. Narcan distribution is up 61%, to over 106,000 doses. That’s not a program failing. That’s a program racing to cover for the one service the city decided was politically radioactive, while the actual infection risk — the thing syringe access exists to prevent — keeps climbing in the space the city cleared for it.
If you’re using in Philadelphia right now and the exchange van isn’t carrying what it used to, the rest of what Prevention Point runs is still there and still free: wound care, buprenorphine, PrEP, and naloxone haven’t been cut, only expanded. That’s worth knowing before you improvise with something less clean. The city didn’t defund harm reduction. It just decided which harm it’s still willing to reduce.
Sources Cited
- 01.B
- 02.BSyringe Access ResourcesNational Harm Reduction Coalition
- 03.AThreading the Needle — How to Stop the HIV Outbreak in Rural IndianaNew England Journal of Medicine
Filed Under
harm-reductionpolicyFentanylNaloxone
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Banning Xylazine Didn't Reduce It. It Just Handed the Drug Supply Something Worse.
A quasi-experimental medRxiv study of state xylazine scheduling laws found no significant reduction in xylazine detections and a rise in the unscheduled, more potent adulterant medetomidine.
Harm ReductionThe FDA Spent a Decade Fighting Flavored Vapes. It Just Quietly Switched Sides.
The FDA has authorized 48 e-cigarette products and 43 nicotine pouch products, including flavored options — a shift from a decade of flavor bans that critics say puts youth vaping risk back on the table.
Harm ReductionThe DEA Tried to Ban Kratom Once. Users Beat It Back. This Time, It's Betting They're Too Sick to Fight.
The DEA's temporary Schedule I order for concentrated 7-OH kratom extracts echoes the agency's 2016 kratom ban attempt — but this time the users most affected may be too physically dependent to fight back the way the last generation did.